| Literature DB >> 25818835 |
Jennifer E Bestman1, Lin-Chien Huang2, Jane Lee-Osbourne3, Phillip Cheung4, Hollis T Cline5.
Abstract
Neurogenesis in the brain of Xenopus laevis continues throughout larval stages of development. We developed a 2-tier screen to identify candidate genes controlling neurogenesis in Xenopus optic tectum in vivo. First, microarray and NanoString analyses were used to identify candidate genes that were differentially expressed in Sox2-expressing neural progenitor cells or their neuronal progeny. Then an in vivo, time-lapse imaging-based screen was used to test whether morpholinos against 34 candidate genes altered neural progenitor cell proliferation or neuronal differentiation over 3 days in the optic tectum of intact Xenopus tadpoles. We co-electroporated antisense morpholino oligonucleotides against each of the candidate genes with a plasmid that drives GFP expression in Sox2-expressing neural progenitor cells and quantified the effects of morpholinos on neurogenesis. Of the 34 morpholinos tested, 24 altered neural progenitor cell proliferation or neuronal differentiation. The candidates which were tagged as differentially expressed and validated by the in vivo imaging screen include: actn1, arl9, eif3a, elk4, ephb1, fmr1-a, fxr1-1, fbxw7, fgf2, gstp1, hat1, hspa5, lsm6, mecp2, mmp9, and prkaca. Several of these candidates, including fgf2 and elk4, have known or proposed neurogenic functions, thereby validating our strategy to identify candidates. Genes with no previously demonstrated neurogenic functions, gstp1, hspa5 and lsm6, were identified from the morpholino experiments, suggesting that our screen successfully revealed unknown candidates. Genes that are associated with human disease, such as such as mecp2 and fmr1-a, were identified by our screen, providing the groundwork for using Xenopus as an experimental system to probe conserved disease mechanisms. Together the data identify candidate neurogenic regulatory genes and demonstrate that Xenopus is an effective experimental animal to identify and characterize genes that regulate neural progenitor cell proliferation and differentiation in vivo.Entities:
Keywords: Candidate gene; Differentiation; In vivo imaging; Microarray; Morpholino; Neural progenitor cell; Neurogenesis; Proliferation; Radial glia
Mesh:
Substances:
Year: 2015 PMID: 25818835 PMCID: PMC4584193 DOI: 10.1016/j.ydbio.2015.03.010
Source DB: PubMed Journal: Dev Biol ISSN: 0012-1606 Impact factor: 3.582
Fig. 1Flow diagram of the protocols for animal rearing, cell isolation, RNA preparation and microarray hybridization. At stage 46 or 48, tadpoles were electro-porated with a GFP-expression construct and placed in one of three visual experience conditions: normal 12 h light:12 h dark conditions; visual deprivation (vd), or enhanced visual experience. These rearing conditions produced 5 cell groups: active NPCs (aNPCs), Mature Neurons, Immature Neurons, Active NPCs isolated from visually-deprived tadpoles (aNPCvd), and quiescent NPCs (qNPCs). See text for details. GFP+ cells were harvested from dissociated midbrains and RNA was isolated and prepared for microarrays. The bottom panel shows which samples were compared by microarray analysis to identify differentially expressed genes that might be involved in cell proliferation and neurogenesis.
Fig. 2Relationships between the multiple microarray comparisons. (A) Venn diagram of the overlap of the transcripts with differential expression (p<0.05) between the 3 microarray comparisons. About 50% of differentially expressed transcripts were shared between the 3 datasets. Sizes of the ovals represent the number of transcripts showing significant differential expression in each micro-array comparison. The overlap represents the proportion of transcripts shared by multiple microarray comparisons. The aNPC vs Mature Neuron set contains 1606 transcripts, 672 of which were shared with at least one other group. The aNPC vs qNPC comparison has 932 differentially expressed transcripts, and shared 573 transcripts with other comparisons. The aNPCvd vs Immature Neuron comparison had 702 genes with significant differential expression, with 395 shared between the different comparisons. In total, 124 genes were shared between all 3 gene groups. (B) DAVID analyses reveal gene ontology traits from the microarray comparisons. Differentially expressed transcripts with p<0.05 from the aNPC vs qNPC, aNPC vs Immature Neuron, and aNPC vs Mature Neuron microarray comparisons were clustered using the DAVID Functional Annotation Clustering tool. The enriched gene clusters are shown in pie charts for each comparison. The number of transcripts identified in each cluster is indicated in the diagram or in the legend. Transcripts in the nucleosome and chromatin assembly pathways (black) were common to all three microarray comparisons. The RNA recognition RNP-1 family (white) was abundant in both the aNPCvd vs Immature Neuron and the aNPC vs Mature Neurons microarray comparisons. These data are provided in Supplementary Table 2.
Fig. 3aNPCs share networks of differentially expressed transcripts. (A) Networks of differentially-expressed transcripts that are shared between NPCs. Transcripts with positive expression values (more highly expressed in NPCs) or negative expression values (more highly expressed in neurons or quiescent NPCs) were analyzed separately. Each node of the network indicates the groups of positively (blue) or negatively (red)-expressed genes for each microarray comparison, nodes separated by short distances and thicker connections indicate that the groups share many transcripts. The size of the pie diagram at each node represents the total number of differentially expressed genes and the number of unique genes unshared (black) and shared between groups (blue, gray or red). Blue represents genes enriched in aNPCs with high proliferative capability, gray represents enrichment in qNPCs and red indicates enrichment in neurons with the lowest proliferative capability. Numbers on the connecting segments are the numbers of transcripts in common between the groups. (B) DAVID Functional Annotation Clustering tool identified 5 gene families that are enriched in multiple aNPC datasets: nucleosome and chromatin assembly genes, RNA recognition motif RNP-1 family, CHROMO domain containing chromatin binding genes, the TCP-1 chaperonin family and genes associated with oxygen transport.
Fig. 4MetaCore analysis of differentially expressed transcripts in NPCs and Neurons. Map Folders (left column), which identify broad functional categories, and Canonical Pathways Maps (right column), which identify more specific candidate interaction pathways, are listed in the order of significance, from top to bottom of the lists. Pathway Maps that are within Map Folders are color coded. The top 10 significant pathways from MetaCore (p<0.05 and False Discovery Rate <0.05) are presented here. Specific components of the Pathway Maps that were identified in the microarray comparisons are shown in Supplementary Table 3.
Fig. 5Concordance of differentially-expressed transcripts detected by NanoString and microarrays. (A) Pie chart illustrating the degree of concordance of 95 transcripts analyzed by NanoString and microarrays. 49% of transcripts tested by NanoString share the same expression profile as microarray; 25% of transcripts were detected as differentially expressed by only NanoString analysis and 21% were detected as differentially expressed only by microarray analysis. Only 5% of the transcripts that were differentially expressed in the NanoString analysis exhibited differential expression in opposite directions in the microarray analysis. (B) Differential expression of transcripts analyzed by NanoString and microarrays for aNPCvd and Immature Neurons. Transcripts that are more highly expressed in aNPCvd than Immature Neurons (green), more highly expressed in Immature Neurons (red) or not differentially expressed (white) are shown for concordant transcripts (NanoString = Microarray) or those that were detected as differentially expressed only by NanoString or microarray. Transcripts to the far right were differentially expressed but in opposite directions between NanoString and microarray analyses.
Morpholino sequences and their target genes.
| MO sequence | Full name | Ref. seq | Unigene ID | |
|---|---|---|---|---|
| GACCCAGGTTTCGCAGACCAGACAT |
| ADP-ribosylation factor-like 9 | NM_001096919 | Xl.66117 |
| GAGGCTCCAACACGCACGCCATCTT |
| Armadillo repeat containing 8 | NM_001096774 | Xl.19526 |
| CGTTGTCGAATAAAGTGAGAGCCAT |
| Chimerin (chimaerin) 1 | NP_001080335 | Xl.56738 |
| GCCAAATTGAATTTCAATGCAATCG |
| Cytoplasmic polyadenylation element binding protein 1 | NM_001090603 | Xl.984 |
| AGGAGCCCCGGAGTCCGCATCATCC |
| CTD nuclear envelope phosphatase 1 (dullard) | NM_001096787 | Xl.76057 |
| GCAGTGCAACATGGTGCTCAGCCCT |
| Deiodinase, iodothyronine, type 3 | NM_001087863 | Xl.862 |
| AAAGAAGCACAAACACCACAGCCAT |
| Ephrin-A3 | NM_001087027 | Xl.47030 |
| AAGTAGACCGGCATTGCGGCAGATA |
| Eukaryotic translation initiation factor 3 subunit A | NM_001091816 | Xl.3189 |
| GCCACAAAGTGATAGCACTATCCAT |
| ELK4, ETS-domain protein (SRF accessory protein 1) | NM_001085854 | Xl.782 |
| GTAGCAGCAGCACATTTAGTTCCAT |
| EPH receptor B1 | NM_001090601 | Xl.1028 |
| CAGGAGCCATTTTCTGTAGCACAAA |
| Eosinophil peroxidase | NM_001088379 | Xl.424 |
| CCACAGACAGCAGTTCCTGATTCAT |
| F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase | NM_001095717 | Xl.32837 |
| GAGTTGTGATGCTCCCTGCCGCCAT |
| Fibroblast growth factor 2 (basic) | NM_001099871 | Xl.76214 |
| AGCTCCTCCATGTTGCGTCCGCACA |
| Fragile X mental retardation 1 | NM_001085687 | Xl.3332 |
| GCACTTCCACCGTCATGTCCTCCAT |
| Fragile X mental retardation, autosomal homolog 1 | NM_001088317 | Xl.331 |
| TCTTCTTTGGTCTTTCCAAAATGCC |
| GLIS family zinc finger 2 | NM_001088623 | Xl.30097 |
| AATAGGTGAGGACGTAGCCAGGCAT |
| Glutathione S-transferase pi 1 | NM_001088783 | Xl.54920 |
| ACTCAGCCAATTTCTTTTCCATAGC |
| Histone acetyltransferase 1 | NM_001094404 | Xl.43663 |
| GGGCACTAGACACAAACAAGTGCAC |
| Histone deacetylase 6 | NM_001087017 | Xl.8310 |
| AGGCAAACAGCTTCATGGTCACCAT |
| Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) | NM_001086595 | Xl.21814 |
| GCGCAGGCTCATCCTAGTTTCCTTT |
| LSM6 homolog, U6 small nuclear RNA associated | NM_001093849 | Xl.48776 |
| CGCTCGGCGCAGCGGCCATTTTCTC |
| Methyl CpG binding protein 2 (Rett syndrome) | NM_001088385 | Xl.439 |
| ACGTGTTTGATGCTCATTGCCGCTC |
| Makorin ring finger protein 2 | NM_001096637 | Xl.84320 |
| ATTGTGCTCCTCATAATGATCCATC |
| Uncharacterized protein MGC81191; homolog to ACTN1, actinin, alpha 1 | NM_001091370 | |
| AGACTAAAACTCCCACCCTACCCAT |
| Matrix metallopeptidase 9 (92 kDa gelatinase/type IV collagenase) | NM_001086503 | Xl.526 |
| ATCTGTGAATCCGTTTCATCCATTC |
| Molybdenum cofactor synthesis 3 | NM_001095850 | Xl.52919 |
| TCTTTGTGGTAGCCGCGTTGCCCAT |
| Protein kinase, cAMP-dependent, catalytic, alpha | NM_001099869 | Xl.83942 |
| CGCTTCCACTGTCTCTATCCGCCAT |
| Purine-rich element binding protein A | NM_001093440 | Xl.3084 |
| CATGGGACATCTTCAGCATAATACA |
| R3H domain containing 2 | NM_001095964 | Xl.15158 |
| CATCAGACATTACAGCATCTGCCAT |
| RNA binding protein, fox-1 homolog 2 | NM_001091634 | Xl.14636 |
| AGCCCGGTTTTCCTGCTTGCTCCAT |
| Solute carrier family 12 (Na+/K+/Cl- transporters), member 2 (NKCC1) | NM_001122599 | Xl.84328 |
| TCGGAGGTCTGTTTTGAGGGAACAT |
| Transducin-like enhancer of split 1 (E(sp1) homolog) | NM_001096979 | Xl.57178 |
| AGTGGTTGGATTCCGTGTCCATATC |
| VANGL planar cell polarity protein 1 | NM_001096375 | Xl.2505 |
| TCCAGTTGCGGAAGTGTCTGTGCAT |
| Wingless-type MMTV integration site family, member 7B | NM_001090733 | Xl.229 |
| GCGAAATTCAATTTGAATCCAATGG | Control | - | - | - |
Fig. 6In vivo time-lapse imaging protocol. We electroporated optic tecta of stage 46 tadpoles with pSox2-bd::tGFP and control morpholinos (MO) or MOs targeted against genes of interest. After 24 h, all tGFP-labeled cells in each tectal lobe were imaged at daily intervals over 3 days.Cell proliferation over 2 days and the proportions of labeled NPCs and neurons were determined for each timepoint.
Average proportions of cell types on day 1 with comparisons to control values.
| Radial glial progenitors | Neurons | Unclassified | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Morpholino (N) | %± SEM | Mann-Whitney | % Of control | %± SEM | Mann-Whitney | % Of control | %± SEM | Mann-Whitney | % Of control |
| conMO Group 1 (11) | 43.1 ± 3.4 | - | 99.9 ± 8 | 39.8 ± 3.4 | - | 100 ± 8.6 | 17 ± 4.1 | - | 100 ± 24 |
|
| 51.7 ± 3.4 | 0.5889 | 93.5 ± 6.2 | 41 ± 4.4 | 0.3347 | 114 ± 12.4 | 7.1 ± 3.4 | 0.7803 | 82.5 ± 39.9 |
|
| 54.8 ± 6.6 | 0.6158 | 99.1 ± 11.9 | 29.8 ± 9 | 0.2468 | 82.8 ± 25 | 15.3 ± 4.5 | 0.2407 | 177 ± 52.9 |
|
| 59.3 ± 5.6 | 0.5538 | 107.2 ± 10.1 | 19.9 ± 2.2 |
| 55.3 ± 6.1 | 20.7 ± 4.6 |
| 239.5 ± 53.9 |
|
| 70.1 ± 5.5 |
| 126.6 ± 9.9 | 22.5 ± 6.5 | 0.0474 | 62.7 ± 18.1 | 7.3 ± 2.3 | 0.1157 | 84.5 ± 27.6 |
|
| 65.8 ± 8.4 | 0.1322 | 119 ± 15.2 | 20.5 ± 6.1 |
| 57.1 ± 17.1 | 13.5 ± 3.4 | 0.2763 | 156.2 ± 40.2 |
|
| 54.7 ± 2.2 | 0.9385 | 98.8 ± 3.9 | 30.6 ± 2.6 | 0.5627 | 84.9 ± 7.2 | 14.7 ± 2.9 | 0.1519 | 169.9 ± 34 |
|
| 50.4 ± 4.4 | 0.4136 | 91.2 ± 7.9 | 37.1 ± 4.4 | 1 | 103.1 ± 12.3 | 12.3 ± 2.5 | 0.2106 | 143.1 ± 29.3 |
|
| 59.5 ± 6.8 | 0.6159 | 107.6 ± 12.3 | 30.4 ± 3.9 | 0.5883 | 84.5 ± 10.9 | 10 ± 3.4 | 0.7544 | 115.7 ± 40 |
|
| 52.7 ± 3.7 | 0.7574 | 95.2 ± 6.6 | 27.8 ± 4.6 | 0.4177 | 77.3 ± 12.9 | 19.4 ± 2.8 |
| 224.7 ± 32.5 |
|
| 58.5 ± 3.6 | 0.9692 | 105.8 ± 6.6 | 25.2 ± 2.9 | 0.0825 | 70.1 ± 8.2 | 16.1 ± 1.7 |
| 186.8 ± 20.2 |
|
| 38.8 ± 4.5 |
| 70.1 ± 8.1 | 48.3 ± 3.8 |
| 134.3 ± 10.5 | 12.8 ± 2.2 | 0.1752 | 148.1 ± 25.6 |
|
| 59.7 ± 3.5 | 0.3552 | 107.9 ± 6.5 | 26.9 ± 2.7 | 0.145 | 74.9 ± 7.7 | 13.2 ± 2.4 | 0.1524 | 153.3 ± 28.2 |
|
| 50.2 ± 7.3 | 0.3742 | 90.7 ± 13.2 | 40.2 ± 6.1 | 0.4174 | 111.8 ± 16.9 | 9.5 ± 3.5 | 0.9377 | 109.7 ± 40.9 |
|
| 62 ± 6.6 | 0.5218 | 112.1 ± 12 | 27.1 ± 4.8 | 0.3369 | 75.2 ± 13.4 | 10.8 ± 3.5 | 0.6121 | 125.3 ± 41.1 |
|
| 57 ± 7.4 | 1 | 103.1 ± 13.4 | 36.5 ± 6.3 | 0.7871 | 101.5 ± 17.7 | 6.3 ± 2.7 | 0.55 | 73.5 ± 31.5 |
|
| 62 ± 5.1 | 0.2027 | 112 ± 9.2 | 28.1 ± 4.8 | 0.2797 | 78.2 ± 13.4 | 9.8 ± 1.9 | 0.5599 | 113.4 ± 22.4 |
|
| 42.6 ± 5.2 | 0.0593 | 76.9 ± 9.5 | 47.7 ± 5.7 | 0.081 | 132.6 ± 15.9 | 9.6 ± 1.8 | 0.5914 | 111.3 ± 21.3 |
|
| 54.8 ± 6.7 | 0.6958 | 99 ± 12.2 | 27.8 ± 4.6 | 0.3026 | 77.5 ± 13 | 17.2 ± 4.2 | 0.0998 | 199.5 ± 48.5 |
|
| 46 ± 3.6 | 0.0825 | 83.1 ± 6.5 | 43.9 ± 3.1 | 0.1135 | 121.9 ± 8.8 | 10 ± 0.9 | 0.4385 | 116.1 ± 10.6 |
|
| 51.7 ± 3.9 | 0.4465 | 93.5 ± 7.1 | 32 ± 4.3 | 0.7036 | 89 ± 12.1 | 16.1 ± 2.5 | 0.0745 | 186.6 ± 29.2 |
| conMO Group 2 (12) | 55.3 ± 3.3 | - | 100 ± 6.1 | 35.9 ± 3.7 | - | 100 ± 10.4 | 8.6 ± 2.6 | - | 99.9 ± 31.1 |
|
| 32.2 ± 4.4 |
| 74.7 ± 10.3 | 54.7 ± 3.5 |
| 137.5 ± 8.9 | 13 ± 2.2 | 1 | 76.3 ± 13.4 |
|
| 42.6 ± 8.2 | 0.9092 | 98.8 ± 19.1 | 42.5 ± 6.7 | 0.8197 | 106.9 ± 16.8 | 14.7 ± 2.7 | 0.7034 | 86.7 ± 16.3 |
|
| 29.7 ± 7.7 | 0.1445 | 68.8 ± 18 | 57.2 ± 7.4 | 0.0786 | 143.7 ± 18.6 | 13 ± 4.6 | 0.8798 | 76.7 ± 27.4 |
|
| 27.9 ± 4.8 |
| 64.8 ± 11.3 | 47.4 ± 4.8 | 0.2638 | 119.1 ± 12 | 24.5 ± 3.9 | 0.0817 | 144.4 ± 23.1 |
|
| 56.3 ± 11.5 | 0.3349 | 130.4 ± 26.8 | 16 ± 6.3 |
| 40.2 ± 16 | 27.6 ± 8.9 | 0.2811 | 162.3 ± 52.6 |
|
| 36.8 ± 3.5 | 0.1887 | 85.3 ± 8.2 | 40.4 ± 4.5 | 0.8911 | 101.5 ± 11.4 | 22.7 ± 3.4 | 0.171 | 133.4 ± 20.5 |
|
| 50.5 ± 11.5 | 0.9341 | 117 ± 26.6 | 25.8 ± 7.1 | 0.1264 | 65 ± 18 | 23.5 ± 7.4 | 0.6494 | 138.4 ± 43.8 |
|
| 36 ± 7.9 | 0.0778 | 83.5 ± 18.3 | 39.8 ± 8.2 | 0.9438 | 100.1 ± 20.6 | 24 ± 7.6 | 0.7245 | 141.4 ± 44.7 |
|
| 12.4 ± 4.2 |
| 28.8 ± 9.8 | 74.1 ± 4.4 |
| 186.3 ± 11 | 13.3 ± 3.6 | 0.4685 | 78.5 ± 21.6 |
|
| 15.7 ± 6.1 |
| 36.5 ± 14.2 | 61.7 ± 6.8 |
| 155.1 ± 17.2 | 22.4 ± 7.4 | 0.2079 | 132 ± 43.8 |
|
| 46.2 ± 8 | 0.8207 | 107 ± 18.7 | 45.3 ± 6.4 | 0.6505 | 113.8 ± 16.1 | 8.5 ± 2.7 | 0.2364 | 49.8 ± 15.9 |
|
| 25.3 ± 7.9 | 0.1188 | 58.5 ± 18.4 | 56.6 ± 7.2 | 0.0873 | 142.3 ± 18.2 | 18 ± 4 | 0.546 | 106 ± 23.5 |
|
| 22 ± 8.3 |
| 51 ± 19.4 | 61.2 ± 8.7 |
| 153.9 ± 21.8 | 16.7 ± 3.2 | 0.6507 | 98.1 ± 18.8 |
|
| 46.8 ± 4.6 | 0.5913 | 108.6 ± 10.8 | 37.6 ± 5.6 | 0.4818 | 94.6 ± 14.1 | 15.4 ± 3.2 | 0.7097 | 90.5 ± 19.2 |
| noMO Control (13) | 35.3 ± 4.4 | 0.2022 | 81.8 ± 10.3 | 45.6 ± 3.5 | 0.4512 | 114.7 ± 8.8 | 19 ± 4.3 | 0.9077 | 111.6 ± 25.7 |
| conMO Combined (23) | 49.5 ± 2.7 | - | - | 37.8 ± 2.5 | - | - | 12.67 ± 2.52 | - | - |
Each control morpholino group (conMO group 1 and group 2) is compared to the experimental MO data acquired over the same period (experimental results grouped below each control group). All pSox2-bd::FP labeled cells in a tectal lobe were categorized as neurons, radial glial progenitors or unclassifiable/undifferentiated cells and the mean percent of each cell type and standard error of the mean (SEM) are given. The % of control values ± SEM is calculated by dividing the cell percentage of the experimental group by the control value. Mann-Whitney Unpaired tests were conducted for differences in the percent of each cell type compared to control values and the p-values are given. Significant differences from control values are in bold. N=number of electroporated tecta examined. The “conMO Combined” data averages all control MO values and is displayed in Figs. 7 and 8; it is not used for statistical comparisons.
Average proliferation rates between day 1 and day 3 with comparisons to control values.
| Morpholino | Tectal lobe# | Total cell # | Cell proliferation rate between day 1 and day 3 mean ± SEM | Mann-Whitney Unpaired | % of control cell proliferation rate mean ± SEM |
|---|---|---|---|---|---|
| conMO Group 1 | 12 | 247 | 23.5 ± 5.5 | 0.8052 | 100 ± 23.5 |
|
| 8 | 304 | 73.8 ± 15.4 |
| 314.8 ± 65.6 |
|
| 8 | 277 | 179.1 ± 49.8 |
| 763.9 ± 212.7 |
|
| 7 | 371 | 96.4 ± 23.1 |
| 411.1 ± 98.5 |
|
| 8 | 215 | 97.4 ± 26.9 |
| 415.5 ± 114.5 |
|
| 8 | 300 | 40.9 ± 8.1 | 0.097 | 174.4 ± 34.5 |
|
| 8 | 423 | 50.8 ± 18.4 | 0.202 | 216.4 ± 78.7 |
|
| 9 | 407 | 64.7 ± 9.4 |
| 275.9 ± 40.3 |
|
| 8 | 300 | 63.8 ± 15.4 |
| 271.6 ± 65.7 |
|
| 8 | 417 | 46.9 ± 5.4 |
| 200 ± 23.1 |
|
| 8 | 438 | 78.8 ± 16.3 |
| 336.4 ± 69.9 |
|
| 8 | 288 | 44 ± 7.3 | 0.058 | 187.8 ± 31.3 |
|
| 9 | 367 | 69.3 ± 15.1 |
| 295.7 ± 64.3 |
|
| 8 | 221 | 9.3 ± 9.5 | 0.177 | 39.5 ± 40.5 |
|
| 8 | 238 | 124.5 ± 31.1 |
| 531.3 ± 132.5 |
|
| 8 | 232 | 48.1 ± 11.3 | 0.089 | 205 ± 48.2 |
|
| 8 | 278 | 37.9 ± 8.2 | 0.203 | 161.6 ± 34.9 |
|
| 9 | 394 | 44.4 ± 21.1 | 0.722 | 189.3 ± 90 |
|
| 8 | 309 | 31 ± 6.4 | 0.396 | 132.1 ± 27.1 |
|
| 8 | 300 | 20.1 ± 4.5 | 0.877 | 85.8 ± 19.3 |
|
| 7 | 237 | 34.4 ± 21.8 | 0.704 | 146.5 ± 92.9 |
| conMO Group 2 | 11 | 296 | 20.8 ± 4.1 | 0.8052 | 100 ± 19.8 |
|
| 10 | 157 | 6.2 ± 3.8 |
| 29.5 ± 18.7 |
|
| 9 | 104 | 34.8 ± 14.4 | 0.676 | 167.3 ± 69.3 |
|
| 6 | 66 | 12.9 ± 5.1 | 0.159 | 62.1 ± 24.7 |
|
| 11 | 322 | 37.7 ± 8.04 |
| 181.7 ± 38.7 |
|
| 5 | 91 | 115.6 ± 30.2 |
| 556.7 ± 145.5 |
|
| 14 | 385 | 15.1 ± 4.2 | 0.338 | 73.1 ± 20.4 |
|
| 9 | 185 | –10.5 ± 11.2 |
| –47.8 ± 61.1 |
|
| 10 | 101 | –3.2 ± 13.9 |
| –15.4 ± 66.8 |
|
| 7 | 163 | 1.5 ± 6.3 |
| 7.4 ± 30.7 |
|
| 6 | 172 | 14.4 ± 13.5 | 0.291 | 68.8 ± 65.1 |
|
| 7 | 121 | –2.6 ± 14.6 |
| –12.2 ± 70.2 |
|
| 6 | 117 | –1.8 ± 8.3 |
| –8.7 ± 39.8 |
|
| 6 | 98 | –10.7 ± 6.4 |
| –51.5 ± 30.7 |
|
| 8 | 119 | 11.2 ± 11.6 | 0.231 | 53.8 ± 56.1 |
| noMO Control | 13 | 208 | 52.7 ± 14 | 0.118 | 253.7 ± 67.3 |
| conMO Combined | 23 | 543 | - | 100 ± 15.15 |
Each control morpholino group (conMO group 1 and group 2) is compared to the experimental MO data acquired over the same period (experimental results grouped below each control group). All pSox2-bd::FP labeled cells in a tectal lobe were counted on days 1 and 3 and the mean differences and standard error of the mean (SEM) are given. The % of control levels ± SEM is calculated by dividing the proliferation rate of the experimental group by the mean control proliferation rate. Mann-Whitney Unpaired tests were conducted for differences in the proliferation rates to the control values and the p-values are given. Significant differences from control values are in bold. The “conMO Combined” value is the average averages of all MO control values and is displayed in Figs. 7 and 8, but it is not used for statistical comparisons.
Fig. 7Morpholinos against candidate neurogenic genes alter cell proliferation and differentiation. A1–D3 Projections of confocal stacks of the right tectal lobe imaged 1 day after co-electroporation with pSox2-bd::tGFP and control morpholinos (A1–A3), or morpholinos against glutathione S-transferase pi 1 (gstp1; B1–B3), armadillo repeat containing 8 (armc8; C1–C3), or heat shock protein 5 (hspa5; D1–D3), GFP-labeled cells are relatively sparse on day 1 (A1, B1, C1, D1). Arrows point to the distal pial endfoot of example neural progenitor cells and asterisks indicate neurons. Under control conditions, the number of NPCs decreases over the subsequent two days (A2 and A3). The tectal lobes with targeted gene knockdown show decreases (gstp1 and hspa5) and increases (armc8) in cell proliferation, as well as higher proportions of NPCs (hspa5) or neurons (gstp1 and armc8) on the third day of imaging. A4–D4, A5–D5 Summary graphs of changes in the proportion of cells in the tectum of the control (A) and morpholino-treated (B–D) animals that are NPCs (A4–D4) or neurons (A5–D5). Each line represents data from a separate animal. An asterisk over day 1 or day 3 indicates a significant difference from the mean control values (Mann–Whitney U test, p<0.05) and an asterisk over the center bracket indicates that there was a significant change between day 1 and day 3 levels (Wilcoxon Signed Rank test, p<0.05). Summary graphs for all control and morpholino results are provided in Supplementary Fig. 1. Data are shown in Tables 2–5.
Pairwise comparisons of changing percentages of cell types between day 1 and day 3.
| % Neural progenitor cells | % Neurons | % Unclassified | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Morpholino | Day 1 | Day 3 | Wilcoxon | Day 1 | Day 3 | Wilcoxon | Day 1 | Day 3 | Wilcoxon |
| conMO group 1 | 55.4 ± 3.4 | 27.9 ± 4.7 | 0.0005 | 36 ± 3.8 | 61.7 ± 5 | 0.0024 | 8.7 ± 2.7 | 10.3 ± 2.7 | 0.5693 |
|
| 51.8 ± 3.5 | 18.8 ± 3.5 | 0.0078 | 41 ± 4.5 | 62.3 ± 4.6 | 0.0078 | 7.1 ± 3.5 | 18.9 ± 3.2 |
|
|
| 54.9 ± 6.6 | 10.1 ± 2.4 | 0.0078 | 29.8 ± 9 | 74.7 ± 4.5 | 0.0078 | 15.3 ± 4.6 | 15.2 ± 2.9 | 0.9453 |
|
| 59.4 ± 5.6 | 8.3 ± 1.9 | 0.0156 | 19.9 ± 2.2 | 67.5 ± 3.3 | 0.0156 | 20.7 ± 4.7 | 24.3 ± 2.9 | 0.4688 |
|
| 70.1 ± 5.5 | 21.6 ± 4.2 | 0.0078 | 22.6 ± 6.5 | 64.7 ± 3.9 | 0.0078 | 7.3 ± 2.4 | 13.7 ± 2.5 | 0.1953 |
|
| 54.7 ± 2.2 | 22.2 ± 3 | 0.0078 | 30.6 ± 2.6 | 58.2 ± 3.8 | 0.0078 | 14.7 ± 2.9 | 19.6 ± 1.7 | 0.1094 |
|
| 50.5 ± 4.4 | 23.9 ± 4.8 | 0.0039 | 37.1 ± 4.5 | 62.4 ± 5.1 | 0.0078 | 12.4 ± 2.5 | 13.7 ± 1.7 | 0.8209 |
|
| 59.6 ± 6.9 | 13.7 ± 2.9 | 0.0078 | 30.4 ± 4 | 75.9 ± 3.2 | 0.0078 | 10 ± 3.5 | 10.4 ± 2.8 | 0.2969 |
|
| 52.7 ± 3.7 | 25.2 ± 2.2 | 0.0078 | 27.8 ± 4.7 | 56.1 ± 1.9 | 0.0078 | 19.4 ± 2.8 | 18.7 ± 0.9 | 0.7422 |
|
| 58.6 ± 3.7 | 18.6 ± 2.3 | 0.0078 | 25.3 ± 3 | 62.5 ± 3.5 | 0.0078 | 16.2 ± 1.7 | 19 ± 2.3 | 0.25 |
|
| 38.8 ± 4.5 | 17.3 ± 3.3 | 0.0078 | 48.4 ± 3.8 | 68.2 ± 3.4 | 0.0234 | 12.8 ± 2.2 | 14.5 ± 3.1 | 0.8438 |
|
| 50.2 ± 7.3 | 20.5 ± 4 | 0.0078 | 40.3 ± 6.1 | 71.1 ± 4.4 | 0.0078 | 9.5 ± 3.5 | 8.4 ± 2.2 | 0.8438 |
|
| 59.8 ± 3.6 | 17.3 ± 3 | 0.0039 | 27 ± 2.8 | 69.7 ± 3.5 | 0.0039 | 13.3 ± 2.4 | 13 ± 2.7 | 0.9102 |
|
| 62.1 ± 6.7 | 17.9 ± 4 | 0.0039 | 27.1 ± 4.9 | 73 ± 3.6 | 0.0039 | 10.8 ± 3.6 | 9.1 ± 1.5 | 0.6523 |
|
| 57.1 ± 7.4 | 23.1 ± 3.1 | 0.0156 | 36.6 ± 6.4 | 68.2 ± 3.2 | 0.0156 | 6.4 ± 2.7 | 8.7 ± 2.3 | 0.4375 |
|
| 62 ± 5.1 | 27.4 ± 5.1 | 0.0078 | 28.2 ± 4.8 | 55.7 ± 4.3 | 0.0078 | 9.8 ± 1.9 | 16.9 ± 2 |
|
|
| 42.6 ± 5.3 | 22.7 ± 3.5 | 0.0391 | 47.8 ± 5.7 | 66 ± 4.8 | 0.0195 | 9.6 ± 1.8 | 11.3 ± 3.1 | 0.7344 |
|
| 54.8 ± 6.8 | 22.9 ± 4.6 | 0.0039 | 27.9 ± 4.7 | 62.9 ± 5.2 | 0.0039 | 17.3 ± 4.2 | 14.2 ± 2.4 | 0.3594 |
|
| 46 ± 3.6 | 20.5 ± 2.7 | 0.0078 | 43.9 ± 3.2 | 70.8 ± 3 | 0.0078 | 10.1 ± 0.9 | 8.7 ± 1.8 | 0.3125 |
|
| 51.8 ± 3.9 | 16.3 ± 3.1 | 0.0156 | 32.1 ± 4.4 | 74 ± 3.6 | 0.0156 | 16.1 ± 2.5 | 9.7 ± 1.1 | 0.1094 |
| conMO group 2 | 43.2 ± 3.5 | 21.6 ± 3.3 | < 0.0001 | 39.8 ± 3.4 | 56.5 ± 5.6 | < 0.0001 | 17 ± 4.1 | 21.9 ± 4.4 | 0.1973 |
|
| 32.3 ± 4.5 | 17.5 ± 4.4 | 0.0195 | 54.7 ± 3.6 | 70.7 ± 4.9 | 0.0078 | 13 ± 2.3 | 11.8 ± 2.1 | 1 |
|
| 42.7 ± 8.3 | 28.1 ± 7.4 | 0.0313 | 42.6 ± 6.7 | 51.9 ± 5.8 |
| 14.8 ± 2.8 | 20 ± 3.1 | 0.1094 |
|
| 29.7 ± 7.8 | 27 ± 3.9 |
| 57.2 ± 7.4 | 57.4 ± 4 | 1 | 13.1 ± 4.7 | 15.6 ± 1.7 | 0.6875 |
|
| 65.9 ± 8.5 | 12.6 ± 2.5 | 0.0078 | 20.6 ± 6.2 | 71.9 ± 3.1 | 0.0078 | 13.5 ± 3.5 | 15.6 ± 2.1 | 0.5469 |
|
| 28 ± 4.9 | 14.9 ± 2 | 0.0029 | 47.4 ± 4.8 | 60.8 ± 4.8 | 0.0273 | 24.6 ± 3.9 | 24.3 ± 3.7 | 0.7646 |
|
| 56.3 ± 11.6 | 26.1 ± 4.6 |
| 16 ± 6.4 | 50.9 ± 5 |
| 27.6 ± 9 | 23 ± 4 | 0.8125 |
|
| 36.9 ± 3.6 | 18.6 ± 3 | 0.0004 | 40.4 ± 4.6 | 58.1 ± 3.5 | 0.0023 | 22.7 ± 3.5 | 23.4 ± 3.3 | 0.9515 |
|
| 50.5 ± 11.5 | 20.3 ± 5.5 | 0.0078 | 25.9 ± 7.2 | 60.6 ± 6.9 | 0.0078 | 23.6 ± 7.5 | 19 ± 4.7 | 0.8125 |
|
| 36.1 ± 7.9 | 21.4 ± 6.1 | 0.0117 | 39.9 ± 8.2 | 58 ± 6.4 | 0.0039 | 24.1 ± 7.6 | 20.6 ± 6.4 | 0.4375 |
|
| 12.5 ± 4.3 | 5.7 ± 1.9 |
| 74.2 ± 4.4 | 85.5 ± 2.3 |
| 13.4 ± 3.7 | 8.8 ± 1.6 | 0.2188 |
|
| 15.8 ± 6.2 | 8.7 ± 4.9 |
| 61.7 ± 6.9 | 71.5 ± 9.2 |
| 22.5 ± 7.5 | 19.8 ± 6.3 | 0.8438 |
|
| 46.2 ± 8.1 | 50.6 ± 6.7 |
| 45.3 ± 6.4 | 36.9 ± 4.1 |
| 8.5 ± 2.7 | 12.5 ± 4.6 | 0.2188 |
|
| 25.3 ± 7.9 | 10.6 ± 5.5 | 0.0313 | 56.7 ± 7.3 | 73.2 ± 8.3 |
| 18.1 ± 4 | 16.2 ± 5.5 | 1 |
|
| 22 ± 8.4 | 11.3 ± 5.2 |
| 61.3 ± 8.7 | 73.1 ± 7 |
| 16.7 ± 3.2 | 15.6 ± 3.4 | 1 |
|
| 46.9 ± 4.7 | 34.8 ± 7.9 |
| 37.7 ± 5.6 | 53.6 ± 6.1 |
| 15.4 ± 3.3 | 11.5 ± 5.3 | 0.2969 |
| No morpholino | 35.3 ± 4.5 | 14.2 ± 3.4 | 0.0017 | 45.7 ± 3.5 | 63 ± 3.8 | 0.0017 | 19 ± 4.4 | 22.9 ± 4.3 | 0.2163 |
| conMO Combined | 49.5 ± 2.7 | 24.9 ± 2.9 | - | 37.8 ± 2.5 | 59.2 ± 3.7 | - | 12.7 ± 2.5 | 15.9 ± 2.8 | - |
Tecta were electroporated with pSox2-bd::FP (either Kaede or tGFP) alone or combined with the control morpholino (conMO) or one of the 34 experimental morpholinos. The proportions of each cell type were calculated on days 1 and 3 and the means, standard error of the mean (SEM) are given. Wilcoxon Signed Rank tests were used to determine whether the proportions of the neural progenitor cells, neurons or unclassifiable cells changed significantly between day 1 and day 3 p-values. Significant differences from control values are in bold.
Proportions of cell types generated by day 3 with comparisons to control values.
| Proportion of cell types, day 3 | % of control levels ± SEM | Pearson's Chi-square | Mann Whitney Unpaired | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Morpholino | % Progenitors | % Neurons | % Unclassified | Progenitors | Neurons | Unclassified | Progenitors | Neurons | Unclassified | |
| conMO Group 1 | 21.5 ± 10.8 | 56.5 ± 5.5 | 21.9 ± 4.4 | 100 ± 15.1 | 100 ± 9.8 | 100 ± 20.3 | - | - | - | - |
|
| 18.8 ± 9.8 | 62.2 ± 4.5 | 18.8 ± 3.1 | 67.4 ± 12.4 | 100.8 ± 7.4 | 182.8 ± 30.5 |
| 0.2311 | 0.589 | 0.059 |
|
| 10.1 ± 6.8 | 74.7 ± 4.5 | 15.1 ± 2.9 | 36.2 ± 8.6 | 121 ± 7.3 | 146.8 ± 28.4 |
|
| 0.037 | 0.203 |
|
| 8.2 ± 4.8 | 67.4 ± 3.3 | 24.2 ± 2.9 | 29.6 ± 6.6 | 109.2 ± 5.4 | 235 ± 28.4 |
|
| 0.22 | 0.008 |
|
| 21.6 ± 11.9 | 64.6 ± 3.9 | 13.7 ± 2.5 | 77.2 ± 15.1 | 104.7 ± 6.3 | 132.8 ± 24.5 | 0.081 | 0.2969 | 0.487 | 0.216 |
|
| 12.5 ± 6.9 | 71.8 ± 3.1 | 15.5 ± 2 | 44.9 ± 8.8 | 116.4 ± 5 | 150.9 ± 20.1 |
| 0.0583 | 0.083 | 0.105 |
|
| 22.2 ± 8.3 | 58.2 ± 3.8 | 19.6 ± 1.7 | 79.4 ± 10.6 | 94.2 ± 6.1 | 190 ± 16.5 |
| 0.2463 | 0.908 |
|
|
| 23.9 ± 14.5 | 62.3 ± 5.1 | 13.6 ± 1.6 | 85.6 ± 17.3 | 101 ± 8.2 | 132.5 ± 16.2 |
| 0.569 | 0.57 | 0.145 |
|
| 13.7 ± 8.2 | 75.8 ± 3.1 | 10.4 ± 2.7 | 49 ± 10.4 | 122.8 ± 5.1 | 101.2 ± 26.7 |
| 0.0693 | 0.083 | 0.816 |
|
| 25.2 ± 6.3 | 56 ± 1.9 | 18.7 ± 0.9 | 90.2 ± 8 | 90.8 ± 3.1 | 181.4 ± 8.8 |
| 0.3341 | 0.7 |
|
|
| 18.6 ± 6.5 | 62.4 ± 3.4 | 18.9 ± 2.2 | 66.5 ± 8.3 | 101.1 ± 5.6 | 183.6 ± 21.8 |
| 0.2023 | 0.512 |
|
|
| 17.3 ± 9.2 | 68.1 ± 3.4 | 14.5 ± 3 | 62 ± 11.6 | 110.4 ± 5.5 | 140.4 ± 29.6 |
| 0.1444 | 0.136 | 0.455 |
|
| 17.2 ± 9 | 69.7 ± 3.4 | 12.9 ± 2.7 | 61.9 ± 10.7 | 112.9 ± 5.6 | 125.6 ± 26.6 |
| 0.1319 | 0.154 | 0.354 |
|
| 20.5 ± 11.2 | 71.1 ± 4.3 | 8.4 ± 2.2 | 73.3 ± 14.1 | 115.1 ± 7.1 | 81.4 ± 21.5 | 0.397 | 0.1641 | 0.097 | 0.938 |
|
| 17.8 ± 11.8 | 73 ± 3.5 | 9.1 ± 1.4 | 63.8 ± 14.1 | 118.3 ± 5.7 | 88.2 ± 14.2 |
| 0.1346 | 0.114 | 0.877 |
|
| 23.1 ± 8.7 | 68.1 ± 3.2 | 8.7 ± 2.2 | 82.7 ± 11 | 110.4 ± 5.2 | 84.3 ± 21.9 | 0.766 | 0.3536 | 0.19 | 0.907 |
|
| 27.3 ± 14.3 | 55.7 ± 4.3 | 16.8 ± 2 | 97.9 ± 18.1 | 90.2 ± 7 | 163.7 ± 19.7 | 0.067 | 0.9692 | 0.847 | 0.07 |
|
| 22.7 ± 10.4 | 65.9 ± 4.7 | 11.2 ± 3.1 | 81.3 ± 12.4 | 106.8 ± 7.7 | 109.4 ± 30.1 | 0.317 | 0.213 | 0.5 | 0.695 |
|
| 22.8 ± 13.6 | 62.9 ± 5.1 | 14.2 ± 2.3 | 81.7 ± 16.3 | 101.9 ± 8.4 | 137.7 ± 23.2 | 0.118 | 0.4335 | 0.335 | 0.231 |
|
| 20.5 ± 7.6 | 70.8 ± 2.9 | 8.6 ± 1.7 | 73.5 ± 9.6 | 114.6 ± 4.8 | 83.9 ± 17.4 | 0.073 | 0.2162 | 0.143 | 1 |
|
| 16.3 ± 8.3 | 73.9 ± 3.5 | 9.7 ± 1 | 58.3 ± 11.2 | 119.8 ± 5.8 | 94 ± 10.2 |
| 0.1624 | 0.099 | 0.582 |
| conMO Group 2 | 27.9 ± 16.1 | 61.7 ± 4.9 | 10.3 ± 2.7 | 100 ± 16.6 | 99.9 ± 8 | 100 ± 26.5 |
|
|
|
|
|
| 17.5 ± 13.9 | 70.7 ± 4.9 | 11.7 ± 2.1 | 80.9 ± 20.3 | 125.1 ± 8.7 | 53.7 ± 9.7 | 0.259 | 0.3787 | 0.149 | 0.17 |
|
| 28.1 ± 22 | 51.8 ± 5.7 | 20 ± 3 | 130.2 ± 34 | 91.7 ± 10.1 | 91.4 ± 14 | 0.149 | 0.5433 | 0.703 | 0.909 |
|
| 27 ± 9.5 | 57.3 ± 3.9 | 15.6 ± 1.6 | 125.1 ± 18 | 101.4 ± 7 | 71.3 ± 7.6 | 0.551 | 0.4211 | 0.92 | 0.651 |
|
| 14.9 ± 6.6 | 60.7 ± 4.7 | 24.2 ± 3.7 | 69.1 ± 9.3 | 107.5 ± 8.4 | 110.9 ± 16.9 |
| 0.1075 | 0.511 | 0.108 |
|
| 26 ± 10.1 | 50.9 ± 5 | 23 ± 4 | 120.6 ± 21.1 | 90 ± 8.8 | 105.2 ± 18.2 |
| 0.5711 | 0.571 | 0.91 |
|
| 18.5 ± 11 | 58 ± 3.5 | 23.3 ± 3.2 | 86 ± 13.6 | 102.7 ± 6.2 | 106.7 ± 14.9 | 0.083 | 0.4595 | 0.722 | 0.805 |
|
| 20.3 ± 15.6 | 60.6 ± 6.9 | 19 ± 4.7 | 94.1 ± 25.6 | 107.2 ± 12.2 | 86.9 ± 21.4 | 0.582 | 0.8365 | 0.71 | 0.649 |
|
| 21.4 ± 19.3 | 57.9 ± 6.4 | 20.5 ± 6.3 | 99.3 ± 28.3 | 102.6 ± 11.3 | 93.9 ± 29.1 | 0.041 | 0.7512 | 0.916 | 0.596 |
|
| 5.6 ± 4.9 | 85.4 ± 2.3 | 8.8 ± 1.5 | 26.2 ± 8.5 | 151.2 ± 4.1 | 40.3 ± 7.3 |
|
|
|
|
|
| 8.6 ± 12 | 71.5 ± 9.1 | 19.7 ± 6.2 | 40.2 ± 22.6 | 126.5 ± 16.2 | 90.4 ± 28.7 |
|
| 0.107 | 0.725 |
|
| 50.6 ± 17.6 | 36.9 ± 4.1 | 12.5 ± 4.5 | 234.3 ± 30.9 | 65.2 ± 7.2 | 57.1 ± 20.8 |
|
|
| 0.204 |
|
| 10.6 ± 13.5 | 73.2 ± 8.2 | 16.1 ± 5.4 | 49.1 ± 25.5 | 129.5 ± 14.6 | 73.9 ± 25.1 |
| 0.0559 | 0.097 | 0.451 |
|
| 11.2 ± 12.7 | 73.1 ± 7 | 15.6 ± 3.3 | 52.1 ± 24 | 129.3 ± 12.3 | 71.3 ± 15.3 | 0.062 | 0.1074 | 0.097 | 0.514 |
|
| 34.8 ± 22.4 | 53.6 ± 6 | 11.5 ± 5.3 | 161.3 ± 36.7 | 94.8 ± 10.7 | 52.6 ± 24.4 | 0.071 | 0.1731 | 0.836 | 0.083 |
| No morpholino | 14.1 ± 12.4 | 62.9 ± 3.8 | 22.8 ± 4.2 | 65.6 ± 15.9 | 111.3 ± 6.7 | 104.5 ± 19.4 | 0.359 | 0.1245 | 0.401 | 0.794 |
| conMO Combined | 21.5 ± 10.8 | 59.2 ± 3.7 | 15.9 ± 2.8 | 100 ± 15.1 | 100 ± 9.8 | 100 ± 20.3 | - | - | - | - |
Each control morpholino group (conMO group 1 and group 2) is compared to the experimental MO data acquired over the same period (experimental results grouped below each control group). All pSox2-bd::FP labeled cells in a tectal lobe were categorized as neurons, radial glial progenitors or unclassifiable/undifferentiated cells and the mean percent of each cell type and standard error of the mean (SEM) are given. The % of control values ± SEM is calculated by dividing the cell percentage of the experimental group by the control value. Pearson Chi-square values for differences in the distributions of cell populations between each control morpholino group (conMO groupl or conMO group 2) and experimental morpholino groups are given. Mann-Whitney Unpaired tests were conducted for differences in the percent of each cell type to the control values and the p-values are given. Significant differences from control values are in bold. The “conMO Combined” value averages all control MO values and is displayed in Figs. 7 and 8; it is not used for statistical comparisons.
Fig. 8Morpholinos against candidate neurogenic genes generate a range of neurogenesis phenotypes. Summary of the in vivo imaging data showing the numbers of GFP-labeled cells generated over time (A), the proportion of the cells that were neurons (B) or NPCs (C) for each experimental condition. (A) The genes targeted with morpholinos are arranged by the magnitude of the change in cell number over 3 days. The asterisks indicate a significant decrease or increase compared to control morpholino conditions (red line). The mean values, SEMs and p-values are in Table 4. (B–C) The proportion of neurons (B) and NPCs (C) as a percentage of all cells counted on day 3. The genes targeted are listed along the y-axis and arranged by those that produced the greatest proportion of neurons. Asterisks indicate differences in the proportion of cell types between the experimental and matched control morpholino groups (Mann–Whitney U test, p <0.05). Gene symbols listed in red identify the morpholinos that resulted in a significant difference in the proportions of cell types compared to control (Pearson X-square test, p<0.05). The mean values, SEMs and p-values are in Table 2. Red lines on graphs indicate the mean control morpholino (conMO) values for the proportion of neurons or NPCs. The mean values, SEMs, and p-values are in Table 5.
Summary of screening results from microarray, NanoString and in vivo imaging studies for genes examined by morpholino treatments. 0 means no significant difference in the microarray, NanoString or in vivo analysis of neurogenesis phenotypes. 1 means a significant difference was detected in the assay(s) listed in the column. Concordance refers to the outcome detected in the microarray analysis comparing aNPC(vd) vs immature neurons and the NanoString analysis. If concordance = 1, the outcomes were the same. If concordance = 0, the outcomes were different. Nd = not determined.
| Gene | aNPCvd vs immature neuron | aNPC vs mature neuron | aNPC vs qNPC | Any array call | Nano-String call | Neuro-genesis pheno-type | Array call and neuro-genesis pheno-type | Nano String call and neuro-genesis phenotype | Differential expression by nano String or array | Differential expression and neuro-genesis phenotype | Concordance |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
|
| 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 1 | 0 | 1 | nd | 1 | 1 | 0 | 1 | 1 | nd |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|
| 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
|
| 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
|
| 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
|
| 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
|
| 1 | 1 | 0 | 1 | nd | 1 | 1 | 0 | 1 | 1 | nd |
|
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
|
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
|
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
|
| 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
|
| 1 | 1 | 1 | 1 | nd | 1 | 1 | 0 | 1 | 1 | nd |
|
| 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
|
| 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
|
| 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
|
| 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
|
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 |
|
| 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
|
| 1 | 1 | 1 | 1 | nd | 1 | 1 | 0 | 1 | 1 | nd |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|
| nd | nd | nd | nd | 1 | 1 | nd | 1 | 1 | 1 | nd |
|
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
|
| 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
|
| 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
|
| 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
|
| 1 | 0 | 0 | 1 | nd | 0 | 0 | 0 | 1 | 0 | 0 |
|
| 11 | 10 | 18 | 15 | 26 | 13 | 10 | 26 | 19 | 13 |
Fig. 9Candidate gene sets defined by neurogenesis phenotypes. Categories of neurogenesis phenotypes from morpholinos are shown as colored ellipses where the area of each ellipse is proportional to the number of genes in that category. Of the 34 candidate genes (red) tested with morpholino treatment, 24 significantly altered the proportions of cell types (blue circle, Pearson's Chi-square) and 19 significantly altered the proliferation rate (yellow, Mann–Whitney U test). The morpholinos against 15 candidate genes altered both the cell types generated and the proliferation rate. The overlap between these two categories is shown in green. Among these 15 genes, 5 generated significant differences in the proportions of NPCs (purple, Mann–Whitney U test) and of those, 3 also had significant differences in the number of neurons that were generated (light blue, Mann–Whitney U test). One of the 5 (purple) changed both proliferation rate and NPC number (peach).
Fig. 10Summary of neurogenic outcomes under control conditions and with candidate gene morpholinos. (A) Diagram of NPC fates summarized from in vivo imaging experiments. NPCs can either differentiate into neurons or divide and generate NPCs or neurons. (B) Cartoons of the proportions of NPCs and neurons observed on day 1 and day 3 for control animals and animals electroporated with morpholinos against several candidate genes, which represent a range of neurogenic outcomes found in the present study. In control animals, the proportion of NPCs decreases and the proportion of neurons increases over the observation period. Morpholinos against armc8 result in an exaggerated increase in neurons, gstp1 morpholinos result in a rapid shift in the proportion of NPCs to neurons, whereas hspa5 morpholinos result in an increase in the proportion of NPCs and a decrease in the proportion of neurons.